NASDAQ$RCEL
AVITA Medical Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Achieved significant revenue growth and key FDA approvals.
AVITA Medical reported a strong second quarter with a 42% increase in commercial revenue to $11.7 million. The company received two FDA approvals and submitted a PMA supplement for RECELL GO™.
- Commercial revenue increased by 42% to $11.7 million compared to the same period in 2022.
- Received FDA approval for RECELL to treat full-thickness skin defects.
- Initiated commercial launch of full-thickness skin defects with expanded U.S. commercial organization.
- Submitted PMA supplement for automated cell disaggregation device, RECELL GO™.
Headline financials
Revenue & EPS history
AVITA Medical · Revenue · Quarterly
$11.8M
Revenue by segment
AVITA Medical · $19.3M total across 2 segments · Q1 2026
- Sales Revenue$19.1M—99.0%
- Lease Revenue$187K—1.0%
Forward guidance
The company anticipates FDA approval of RECELL GO by December 27, 2023, expects commercial revenue for the third quarter 2023 to be in the range of $13 to $14 million, and raises commercial revenue for the full year 2023 to an expected range of $51 to $53 million. Gross margin for the full year 2023 is expected to be in the range of 83% to 85%.
Tailwinds
- Anticipate FDA approval of RECELL GO by December 27, 2023
- Conducting post-market study with vitiligo patients
- Pursuing site of service reimbursement for the use of RECELL in the physician office setting, which is expected in 2025
- Commercial revenue for the third quarter 2023 is expected to be in the range of $13 to $14 million
- Raising commercial revenue for the full year 2023 from $49 to $51 million to an expected range of $51 to $53 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
+3.8%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+1.8%
Avg return
30 days after
57%
17 / 30 earnings
Positive
+36.7%
Q4 2022
Best reaction
-25.1%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.4% | -0.5% | -10.1% | |
| Q4 2025 | +11.8% | +15.9% | +18.3% | |
| Q3 2025 | +10.6% | +11.2% | +2.9% | |
| Q2 2025 | -21.2% | +7.1% | -20.8% | |
| Q1 2025 | -25.1% | -28.3% | -34.5% | |
| Q4 2024 | +20.4% | +16.4% | -2.6% | |
| Q3 2024 | -2.0% | +3.9% | +7.3% | |
| Q2 2024 | +19.6% | +20.1% | +10.5% | |
| Q1 2024 | +5.6% | +0.1% | +7.1% | |
| Q4 2023 | -1.7% | +5.2% | -9.8% | |
| Q3 2023 | +9.2% | +29.9% | +32.0% | |
| Q2 2023 | +2.5% | -2.1% | -12.0% | |
| Q1 2023 | -24.5% | -24.2% | +6.8% | |
| Q4 2022 | +36.7% | +48.2% | +41.9% | |
| Q3 2022 | +28.9% | +39.0% | +22.1% | |
| Q2 2022 | -7.1% | -8.7% | -17.8% | |
| Q1 2022 | +9.4% | +10.1% | +8.6% | |
| Q4 2021 | +17.1% | +8.2% | -5.2% | |
| Q3 2021 | +3.5% | -10.7% | -4.6% | |
| Q3 2020 | +3.5% | -10.7% | -4.6% | |
| Q2 2021 | -4.1% | -5.3% | -15.0% | |
| Q1 2021 | -5.4% | -6.4% | -9.6% | |
| Q1 2020 | -5.4% | -6.4% | -9.6% | |
| Q2 2020 | +10.2% | +5.8% | -0.8% | |
| Q3 2019 | +10.2% | +9.5% | +6.2% | |
| Q4 2020 | +10.2% | +9.5% | +6.2% | |
| Q1 2019 | +10.2% | +9.5% | +6.2% | |
| Q4 2019 | -2.5% | -1.9% | +11.4% | |
| Q4 2018 | -2.5% | -1.9% | +11.4% | |
| Q2 2019 | -2.5% | -1.9% | +11.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro